I read with interest the detailed literature review on the management of Parkinson's disease during pregnancy by Young and colleagues. 1 As the authors pointed out, there is a paucity of robust evidence to guide medication management in Parkinson's disease during pregnancy. However, the authors appeared to have omitted amantadine in their review. Although it is not the most commonly used medication in Parkinson's disease, amantadine has perhaps slightly stronger evidence to suggest potential teratogenicity 2 and increased risk of miscarriage 3 and hence should be avoided in women who are trying to conceive or in pregnant women. This was highlighted in another recent systematic review performed by Seier and Hillier, 3 which was also referenced by Young and colleagues in their article.
Disclosures
Ethical Compliance Statement: I confirm that the approval of an ethics committee and patient consent was not required for this work. I confirm that I have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.
Funding Sources and Conflicts of Interest: I have no conflict of interest to declare. This work is not linked to any funding.
Financial Disclosures for the Previous 12 Months: I have no financial disclosures.
References
- 1. Young C, Phillips R, Ebenezer L, Zutt R, Peall KJ. Management of Parkinson's disease during pregnancy: Literature review and multidisciplinary input. Mov Disord Clin Pract 2020;7(4):419–430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Nora J, Nora A, Way G. Cardiovascular maldevelopment associated with maternal exposure to amantadine. Lancet 1975;2:167. [DOI] [PubMed] [Google Scholar]
- 3. Seier M, Hiller A. Parkinson's disease and pregnancy: an updated review. Parkinsonism Relat Disord 2017;40:11–17. [DOI] [PubMed] [Google Scholar]